NSG6005 / NSG 6005: Advanced Pharmacology - Week 1 Quiz (2026/2027) South University
NSG6005 / NSG 6005: ADVANCED PHARMACOLOGY
WEEK 1 QUIZ (LATEST )
South University | Graduate Nursing & Advanced Practice Education
Course: NSG 6005 Advanced Pharmacology | Examination: Week 1 Comprehensive Quiz
Total Questions: 100 | Cognitive Levels: 25% Recall, 50% Application, 25% Analysis
Format: 75% Scenario-based, 25% Direct Knowledge | Aligned with: AACN Essentials of Master's
Education, Advanced Pharmacology Competencies (2026/2027 Edition)
Examination Structure:
Section 1: Pharmacokinetics (20 Questions, Q1-Q20)
Section 2: Pharmacodynamics (20 Questions, Q21-Q40)
Section 3: Pharmacogenomics & Personalized Medicine (15 Questions, Q41-Q55)
Section 4: Drug Development, Regulation, & Safety (15 Questions, Q56-Q70)
Section 5: Prescriptive Authority & Legal/Ethical Issues (15 Questions, Q71-Q85)
Section 6: Patient Education & Medication Adherence (15 Questions, Q86-Q100)
Instructions to the Candidate: Select the single best answer for each question. Each question provides a
rationale grounded in the NSG 6005 curriculum, AACN Essentials of Master's Education, and advanced
pharmacology principles. Review the rationale after answering to consolidate clinical reasoning.
Page 1 Advanced Pharmacology Examination
,NSG6005 / NSG 6005: Advanced Pharmacology - Week 1 Quiz (2026/2027) South University
Section 1: Pharmacokinetics (Q1-Q20)
Q1. A 68-year-old patient with hepatic cirrhosis is prescribed oral propranolol for portal
hypertension. Compared with a patient with normal hepatic function, this patient will most likely
demonstrate which pharmacokinetic change that the APRN must consider when dosing?
A. Increased first-pass metabolism requiring a higher oral dose
B. Decreased first-pass metabolism leading to higher bioavailability and risk of excessive
beta-blockade *[CORRECT]*
C. Enhanced renal excretion compensating for hepatic dysfunction
D. Reduced volume of distribution due to increased plasma protein binding
Correct Answer: B
Rationale: In hepatic cirrhosis, first-pass metabolism is impaired because of reduced functional hepatocyte
mass and portosystemic shunting, so a much larger fraction of the oral dose reaches the systemic circulation,
increasing bioavailability and the risk of excessive beta-blockade. Option A is reversed (first-pass metabolism
decreases, not increases). Renal excretion (C) is not predictably enhanced, and protein binding typically falls
(not rises) because of hypoalbuminemia, which increases (not reduces) the volume of distribution of highly
bound drugs. The NSG 6005 curriculum emphasizes altered drug metabolism in hepatic disease as a core
pharmacokinetic variability factor.
Q2. A patient receives an IV bolus of a drug with a volume of distribution (Vd) of 50 L and total
body clearance (Cl) of 7 L/hr. What is the elimination half-life (t1/2) of this drug? (Use t1/2 =
0.693 x Vd / Cl)
A. Approximately 2.5 hours
B. Approximately 5.0 hours *[CORRECT]*
C. Approximately 7.2 hours
D. Approximately 10.4 hours
Correct Answer: B
Rationale: Half-life is calculated as t1/2 = 0.693 x Vd / Cl = 0.693 x 50 L / 7 L/hr = 34. = approximately
4.95 hours, rounded to 5.0 hours. Option A miscalculates by using 0.35 instead of 0.693; Option C uses an
inverted formula; Option D omits the 0.693 constant. The NSG 6005 curriculum requires APRN candidates to
calculate t1/2 from Vd and Cl because half-life determines dosing interval and time to steady state (4-5
half-lives).
Page 2 Advanced Pharmacology Examination
,NSG6005 / NSG 6005: Advanced Pharmacology - Week 1 Quiz (2026/2027) South University
Q3. Which route of administration bypasses the first-pass effect entirely and is most
appropriate for a drug with extensive hepatic extraction such as nitroglycerin?
A. Oral (PO)
B. Sublingual (SL) *[CORRECT]*
C. Rectal (suppository)
D. Intramuscular (IM)
Correct Answer: B
Rationale: Sublingual administration allows the drug to be absorbed through the oral mucosa directly into the
systemic circulation via the superior vena cava, completely bypassing the portal circulation and hepatic
first-pass metabolism. This is why nitroglycerin is given sublingually for angina; oral nitroglycerin would be
largely inactivated by hepatic metabolism. Rectal administration (C) partially bypasses first-pass for drugs
absorbed by the inferior rectal vein, but approximately 50% still undergoes first-pass via the superior rectal
vein. IM (D) avoids the gut but still encounters first-pass only if the drug is delivered to the liver via the portal
system; IM primarily avoids GI absorption issues. The AACN Essentials emphasize route selection as a clinical
pharmacokinetic application.
Q4. A 78-year-old patient is started on gentamicin for a serious Gram-negative infection. Which
pharmacokinetic parameter must be monitored closely because of age-related decline in renal
function, and what dosing adjustment is appropriate?
A. Monitor hepatic transaminases and reduce the dosing interval
B. Monitor trough and peak serum levels and extend the dosing interval *[CORRECT]*
C. Monitor serum albumin and increase the loading dose
D. Monitor only for clinical response; no level monitoring needed
Correct Answer: B
Rationale: Gentamicin is primarily excreted unchanged by the kidney via glomerular filtration, so age-related
decline in creatinine clearance prolongs half-life and increases the risk of nephrotoxicity and ototoxicity.
Therapeutic drug monitoring of both peak (efficacy) and trough (toxicity) serum concentrations is mandatory,
with extension of the dosing interval based on renal function. Option A is incorrect because gentamicin is not
hepatotoxic. Option C is incorrect because albumin changes affect Vd but do not require a larger loading dose
in the elderly. Option D violates AACN standards for high-risk drug monitoring. The NSG 6005 curriculum
emphasizes aminoglycoside TDM as a paradigm of renal-function-adjusted pharmacokinetics.
Page 3 Advanced Pharmacology Examination
, NSG6005 / NSG 6005: Advanced Pharmacology - Week 1 Quiz (2026/2027) South University
Q5. A drug has a high affinity for plasma proteins (95% bound). The patient develops
hypoalbuminemia (albumin 2.0 g/dL). What pharmacokinetic consequence is most clinically
important, and which drug class is at greatest risk?
A. Increased Vd and decreased free fraction; anticoagulants are at lowest risk
B. Increased free fraction and Vd; highly protein-bound drugs such as warfarin are at greatest
risk *[CORRECT]*
C. Decreased free fraction with no change in Vd; antibiotics are at greatest risk
D. No clinically significant change unless total dose is doubled
Correct Answer: B
Rationale: Hypoalbuminemia reduces the number of binding sites, increasing the free (pharmacologically
active) fraction of highly protein-bound drugs and effectively increasing the volume of distribution because
more drug partitions into tissues. Warfarin (approximately 99% bound to albumin) is the classic high-risk
example; small changes in binding produce large changes in free concentration and anticoagulant effect.
Options A, C, and D either reverse the direction of change or understate risk. The NSG 6005 curriculum
stresses protein-binding changes in hypoalbuminemia as a critical source of pharmacokinetic variability,
especially for narrow-therapeutic-index agents.
Q6. A patient is receiving phenytoin, which follows Michaelis-Menten (saturable) kinetics.
Compared with first-order kinetics, what is the key clinical implication the APRN must
recognize?
A. Half-life remains constant regardless of dose
B. Steady state is reached within 4 half-lives at any dose
C. Small increases in dose can produce disproportionate increases in plasma concentration
and toxicity *[CORRECT]*
D. Doubling the dose reliably doubles the steady-state concentration
Correct Answer: C
Rationale: With Michaelis-Menten kinetics, once metabolizing enzymes approach saturation, small dose
increases produce disproportionately large increases in plasma concentration, dramatically prolonging
apparent half-life and risking toxicity. This is why phenytoin therapeutic drug monitoring is essential and dose
titration must be conservative (e.g., 25-50 mg increments). Options A, B, and D describe first-order kinetics,
which do not apply to phenytoin at therapeutic doses. The NSG 6005 curriculum includes saturable metabolism
as a foundational pharmacokinetic concept and a frequent source of medication errors in advanced practice.
Page 4 Advanced Pharmacology Examination
NSG6005 / NSG 6005: ADVANCED PHARMACOLOGY
WEEK 1 QUIZ (LATEST )
South University | Graduate Nursing & Advanced Practice Education
Course: NSG 6005 Advanced Pharmacology | Examination: Week 1 Comprehensive Quiz
Total Questions: 100 | Cognitive Levels: 25% Recall, 50% Application, 25% Analysis
Format: 75% Scenario-based, 25% Direct Knowledge | Aligned with: AACN Essentials of Master's
Education, Advanced Pharmacology Competencies (2026/2027 Edition)
Examination Structure:
Section 1: Pharmacokinetics (20 Questions, Q1-Q20)
Section 2: Pharmacodynamics (20 Questions, Q21-Q40)
Section 3: Pharmacogenomics & Personalized Medicine (15 Questions, Q41-Q55)
Section 4: Drug Development, Regulation, & Safety (15 Questions, Q56-Q70)
Section 5: Prescriptive Authority & Legal/Ethical Issues (15 Questions, Q71-Q85)
Section 6: Patient Education & Medication Adherence (15 Questions, Q86-Q100)
Instructions to the Candidate: Select the single best answer for each question. Each question provides a
rationale grounded in the NSG 6005 curriculum, AACN Essentials of Master's Education, and advanced
pharmacology principles. Review the rationale after answering to consolidate clinical reasoning.
Page 1 Advanced Pharmacology Examination
,NSG6005 / NSG 6005: Advanced Pharmacology - Week 1 Quiz (2026/2027) South University
Section 1: Pharmacokinetics (Q1-Q20)
Q1. A 68-year-old patient with hepatic cirrhosis is prescribed oral propranolol for portal
hypertension. Compared with a patient with normal hepatic function, this patient will most likely
demonstrate which pharmacokinetic change that the APRN must consider when dosing?
A. Increased first-pass metabolism requiring a higher oral dose
B. Decreased first-pass metabolism leading to higher bioavailability and risk of excessive
beta-blockade *[CORRECT]*
C. Enhanced renal excretion compensating for hepatic dysfunction
D. Reduced volume of distribution due to increased plasma protein binding
Correct Answer: B
Rationale: In hepatic cirrhosis, first-pass metabolism is impaired because of reduced functional hepatocyte
mass and portosystemic shunting, so a much larger fraction of the oral dose reaches the systemic circulation,
increasing bioavailability and the risk of excessive beta-blockade. Option A is reversed (first-pass metabolism
decreases, not increases). Renal excretion (C) is not predictably enhanced, and protein binding typically falls
(not rises) because of hypoalbuminemia, which increases (not reduces) the volume of distribution of highly
bound drugs. The NSG 6005 curriculum emphasizes altered drug metabolism in hepatic disease as a core
pharmacokinetic variability factor.
Q2. A patient receives an IV bolus of a drug with a volume of distribution (Vd) of 50 L and total
body clearance (Cl) of 7 L/hr. What is the elimination half-life (t1/2) of this drug? (Use t1/2 =
0.693 x Vd / Cl)
A. Approximately 2.5 hours
B. Approximately 5.0 hours *[CORRECT]*
C. Approximately 7.2 hours
D. Approximately 10.4 hours
Correct Answer: B
Rationale: Half-life is calculated as t1/2 = 0.693 x Vd / Cl = 0.693 x 50 L / 7 L/hr = 34. = approximately
4.95 hours, rounded to 5.0 hours. Option A miscalculates by using 0.35 instead of 0.693; Option C uses an
inverted formula; Option D omits the 0.693 constant. The NSG 6005 curriculum requires APRN candidates to
calculate t1/2 from Vd and Cl because half-life determines dosing interval and time to steady state (4-5
half-lives).
Page 2 Advanced Pharmacology Examination
,NSG6005 / NSG 6005: Advanced Pharmacology - Week 1 Quiz (2026/2027) South University
Q3. Which route of administration bypasses the first-pass effect entirely and is most
appropriate for a drug with extensive hepatic extraction such as nitroglycerin?
A. Oral (PO)
B. Sublingual (SL) *[CORRECT]*
C. Rectal (suppository)
D. Intramuscular (IM)
Correct Answer: B
Rationale: Sublingual administration allows the drug to be absorbed through the oral mucosa directly into the
systemic circulation via the superior vena cava, completely bypassing the portal circulation and hepatic
first-pass metabolism. This is why nitroglycerin is given sublingually for angina; oral nitroglycerin would be
largely inactivated by hepatic metabolism. Rectal administration (C) partially bypasses first-pass for drugs
absorbed by the inferior rectal vein, but approximately 50% still undergoes first-pass via the superior rectal
vein. IM (D) avoids the gut but still encounters first-pass only if the drug is delivered to the liver via the portal
system; IM primarily avoids GI absorption issues. The AACN Essentials emphasize route selection as a clinical
pharmacokinetic application.
Q4. A 78-year-old patient is started on gentamicin for a serious Gram-negative infection. Which
pharmacokinetic parameter must be monitored closely because of age-related decline in renal
function, and what dosing adjustment is appropriate?
A. Monitor hepatic transaminases and reduce the dosing interval
B. Monitor trough and peak serum levels and extend the dosing interval *[CORRECT]*
C. Monitor serum albumin and increase the loading dose
D. Monitor only for clinical response; no level monitoring needed
Correct Answer: B
Rationale: Gentamicin is primarily excreted unchanged by the kidney via glomerular filtration, so age-related
decline in creatinine clearance prolongs half-life and increases the risk of nephrotoxicity and ototoxicity.
Therapeutic drug monitoring of both peak (efficacy) and trough (toxicity) serum concentrations is mandatory,
with extension of the dosing interval based on renal function. Option A is incorrect because gentamicin is not
hepatotoxic. Option C is incorrect because albumin changes affect Vd but do not require a larger loading dose
in the elderly. Option D violates AACN standards for high-risk drug monitoring. The NSG 6005 curriculum
emphasizes aminoglycoside TDM as a paradigm of renal-function-adjusted pharmacokinetics.
Page 3 Advanced Pharmacology Examination
, NSG6005 / NSG 6005: Advanced Pharmacology - Week 1 Quiz (2026/2027) South University
Q5. A drug has a high affinity for plasma proteins (95% bound). The patient develops
hypoalbuminemia (albumin 2.0 g/dL). What pharmacokinetic consequence is most clinically
important, and which drug class is at greatest risk?
A. Increased Vd and decreased free fraction; anticoagulants are at lowest risk
B. Increased free fraction and Vd; highly protein-bound drugs such as warfarin are at greatest
risk *[CORRECT]*
C. Decreased free fraction with no change in Vd; antibiotics are at greatest risk
D. No clinically significant change unless total dose is doubled
Correct Answer: B
Rationale: Hypoalbuminemia reduces the number of binding sites, increasing the free (pharmacologically
active) fraction of highly protein-bound drugs and effectively increasing the volume of distribution because
more drug partitions into tissues. Warfarin (approximately 99% bound to albumin) is the classic high-risk
example; small changes in binding produce large changes in free concentration and anticoagulant effect.
Options A, C, and D either reverse the direction of change or understate risk. The NSG 6005 curriculum
stresses protein-binding changes in hypoalbuminemia as a critical source of pharmacokinetic variability,
especially for narrow-therapeutic-index agents.
Q6. A patient is receiving phenytoin, which follows Michaelis-Menten (saturable) kinetics.
Compared with first-order kinetics, what is the key clinical implication the APRN must
recognize?
A. Half-life remains constant regardless of dose
B. Steady state is reached within 4 half-lives at any dose
C. Small increases in dose can produce disproportionate increases in plasma concentration
and toxicity *[CORRECT]*
D. Doubling the dose reliably doubles the steady-state concentration
Correct Answer: C
Rationale: With Michaelis-Menten kinetics, once metabolizing enzymes approach saturation, small dose
increases produce disproportionately large increases in plasma concentration, dramatically prolonging
apparent half-life and risking toxicity. This is why phenytoin therapeutic drug monitoring is essential and dose
titration must be conservative (e.g., 25-50 mg increments). Options A, B, and D describe first-order kinetics,
which do not apply to phenytoin at therapeutic doses. The NSG 6005 curriculum includes saturable metabolism
as a foundational pharmacokinetic concept and a frequent source of medication errors in advanced practice.
Page 4 Advanced Pharmacology Examination
